Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.71, FiscalAI reports. The firm had revenue of $45.89 million for the quarter, compared to the consensus estimate of $43.09 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%.

Theravance Biopharma Stock Up 1.3%

TBPH traded up $0.18 during trading on Thursday, hitting $14.01. The company’s stock had a trading volume of 778,453 shares, compared to its average volume of 928,591. The firm’s 50 day moving average price is $18.10 and its two-hundred day moving average price is $16.84. Theravance Biopharma has a 12 month low of $7.90 and a 12 month high of $21.03. The stock has a market capitalization of $709.89 million, a price-to-earnings ratio of 24.58 and a beta of 0.17.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TBPH shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. B. Riley Financial reissued a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, BTIG Research lowered their price objective on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Quarry LP bought a new stake in Theravance Biopharma in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma in the 1st quarter valued at $101,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.